Jim Birchenough
Stock Analyst at Wells Fargo
(2.89)
# 1,406
Out of 5,182 analysts
29
Total ratings
57.89%
Success rate
38.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics | Maintains: Equal-Weight | $3 → $2 | $0.27 | +640.74% | 2 | Dec 31, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $55.72 | +25.63% | 3 | Feb 22, 2024 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $27.20 | +76.47% | 3 | Feb 9, 2022 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $1.37 | +9,389.05% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $3.95 | +254.43% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $54.68 | +165.18% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $138.55 | -54.53% | 5 | Oct 29, 2020 | |
| QURE uniQure | Downgrades: Equal-Weight | $56 | $16.81 | +233.14% | 3 | Jun 25, 2020 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Overweight | $734 | $746.00 | -1.61% | 2 | May 26, 2020 | |
| KZR Kezar Life Sciences | Maintains: Overweight | $300 → $180 | $7.37 | +2,342.33% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $7.62 | +333.07% | 3 | Jun 28, 2018 |
Sangamo Therapeutics
Dec 31, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.27
Upside: +640.74%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $55.72
Upside: +25.63%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $27.20
Upside: +76.47%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $1.37
Upside: +9,389.05%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $3.95
Upside: +254.43%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $54.68
Upside: +165.18%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $138.55
Upside: -54.53%
uniQure
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $16.81
Upside: +233.14%
Regeneron Pharmaceuticals
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $746.00
Upside: -1.61%
Kezar Life Sciences
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $7.37
Upside: +2,342.33%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $7.62
Upside: +333.07%